Holen Sie sich die Stockscreener-App
48.72
1.03%
-0.67
Schlusskurs vom Vortag:
$49.39
Offen:
$49.07
24-Stunden-Volumen:
31,497
Relative Volume:
0.10
Marktkapitalisierung:
$1.57B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.95M
KGV:
-32.79
EPS:
-1.4857
Netto-Cashflow:
$-50.43M
1W Leistung:
-1.21%
1M Leistung:
+1.83%
6M Leistung:
+100.82%
1J Leistung:
+0.00%
1-Tages-Spanne:
$48.01
$49.81
1-Wochen-Bereich:
$46.72
$49.91
52-Wochen-Spanne:
$13.36
$50.16
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Firmenname
Lb Pharmaceuticals Inc
Sektor
Branche
Telefon
917-450-6581
Adresse
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
48.72 | 1.59B | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2026-01-09 | Eingeleitet | Roth Capital | Buy |
| 2025-10-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-06 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-06 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lb Pharmaceuticals Inc Aktie (LBRX) Neueste Nachrichten
Bank of New York Mellon Corp Makes New $1.78 Million Investment in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals (NASDAQ: LBRX) Names Joseph M. Miller as CFO with $530K Salary and 200,000-Share Stock Option - Kalkine Media
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment - Yahoo Finance
LB Pharmaceuticals to Participate in Upcoming September Investor Events - GlobeNewswire
LB Pharmaceuticals Names Joseph M. Miller as CFO, Details Compensation and Severance Package - Kalkine Media
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 4.3%Here's What Happened - MarketBeat
LB Pharmaceuticals (NASDAQ: LBRX) Appoints Joseph M. Miller as CFO with $530K Salary and Equity Incentives - Kalkine Media
LB Pharmaceuticals Inc Announces Appointment of Joseph M. Miller to Chief Financial Officer, Effective September 2, 2026 - marketscreener.com
LB Pharmaceuticals Appoints Joseph Miller as New CFO - TipRanks
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer - The Manila Times
A finance executive who helped launch a lupus drug joins LB Pharmaceuticals - Stock Titan
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright Issues Pessimistic Forecast for LBRX Earnings - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High After Analyst Upgrade - MarketBeat
H.C. Wainwright raises LB Pharmaceuticals price target to $60 By Investing.com - Investing.com India
HC Wainwright Forecasts Strong Price Appreciation for LB Pharmaceuticals (NASDAQ:LBRX) Stock - MarketBeat
Great Lakes Advisors LLC Purchases Shares of 30,410 LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighTime to Buy? - MarketBeat
LB (LBRX) Technical Check: Climbs 1.88% to $47.10 on the Day; Level Position: the $44.74 to $49.46 Range Remains in FocusPositive Gamma - vinanet.vn
LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen - marketbeat.com
LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A - Stock Titan
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook By Investing.com - Investing.com South Africa
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook - Investing.com
Stifel Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $53 - Moomoo
LB PHARMACEUTICALS INC : STIFEL RAISES TARGET PRICE TO $53 FROM $40 - Bitget
LB PHARMACEUTICALS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $55 FROM $40 - webull.com
LB Pharmaceuticals Inc Common Stock (NASDAQ: LBRX) Stock Price, News & Analysis - Kalkine
BMO Capital Markets Increases LB Pharmaceuticals (NASDAQ:LBRX) Price Target to $54.00 - MarketBeat
LBRX SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Form 8K LB Pharmaceuticals Inc For: 11 August - Investing.com India
LB Pharmaceuticals Inc Stock 12‑Month Price Target Raised to $47.67, Implies 4% Upside - TradingView
LB Pharmaceuticals Submits Q2 2026 SEC Form 10-Q Reporting 32.26M Shares Outstanding - Kalkine Media
LB Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
LB Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Form 8K LB Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Q2 Loss Per Share Narrows - Yahoo Finance
LB PHARMACEUTICALS INC Q2 2026: Revenue $0 Net loss $(51.6M), EPS $(1.71) — 10-Q Summary - TradingView
Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, vs. FactSet Est of $0.81 Loss - marketscreener.com
LB Pharmaceuticals Reports Q2 2026 Results, Advances LB-102 Timeline and Pipeline Expansion - Quiver Quantitative
LB Pharmaceuticals reports Q2 2026 net loss of $51.6M, cash $327.8M; pivots LB-102 development - TradingView
LB Pharmaceuticals Q2 net loss widens on higher R&D costs - TradingView
LB Pharmaceuticals Inc.: Q2 Earnings Snapshot - The Daily Gazette
Press Release: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Barchart.com
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
Janus Henderson Group PLC Takes Position in LB Pharmaceuticals Inc $LBRX - MarketBeat
LBRX Q1 2026 Earnings: Narrower Loss of -$0.67 Beats Estimates, Yet Shares Slide 5.23% - vinanet.vn
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
HC Wainwright Issues Optimistic Estimate for LBRX Earnings - MarketBeat
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX) and SpaceX (SPCX) - The Globe and Mail
Price to sales forward of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
Finanzdaten der Lb Pharmaceuticals Inc-Aktie (LBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):